MRK · 10-Q · 2026Q2 · Full report

Products and Technology

Merck & Co., Inc. · 2026-08-07 · Importance 31 · Surprise 42 · In source text

Merck expanded its product portfolio through new formulations, indications, and launches including Keytruda Qlex/Keytruda SC, Capvaxive, Enflonsia, Lipfendra, Idvynso, and Numelvi. Keytruda and Keytruda Qlex received multiple 2026 approvals in ovarian, renal cell, bladder, triple-negative breast, and head and neck cancers, while Capvaxive gained a pediatric indication in the U.S. and Europe. Lipfendra was approved as the first FDA-approved oral PCSK9 inhibitor, and Numelvi was approved as the first and only second-generation JAK inhibitor for allergic dermatitis pruritus in dogs.

Key facts

• Keytruda/Keytruda Qlex combined global sales were $8,366 million in the three months ended June 30, 2026 and $16,400 million in the six months ended June 30, 2026. source
• In February 2026, the FDA approved Numelvi (atinvicitinib tablets), the first and only second-generation JAK inhibitor indicated for control of pruritus associated with allergic dermatitis in dogs six months of age and older. source
• Enflonsia sales were $2 million and $3 million in the second quarter and first six months of 2026, respectively, and the Company anticipates shipments will increase in the second half of 2026. source

Impact estimates